Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Recurrence × ixazomib × Clear all

Phase

Status

Completed 2 Withdrawn 1 Terminated 1 Recruiting 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 7 Leukemia, Myeloid, Acute 2 Waldenstrom Macroglobulinemia 1 Triple Negative Breast Neoplasms 1 Recurrence 1 Neoplasms 1 Lymphoma, Mantle-Cell 1 Lymphoma, B-Cell 1 Lymphoma 1 Leukemia, Myelomonocytic, Acute 1 Leukemia, Monocytic, Acute 1 Leukemia, Megakaryoblastic, Acute 1 Leukemia, Erythroblastic, Acute 1 Leukemia 1 Genetic Diseases, Inborn 1 Congenital Abnormalities 1 Breast Neoplasms 1

Interventions

Cyclophosphamide 21 Dexamethasone 19 Rituximab 16 Cytarabine 16 fludarabine 10 Methotrexate 10 Gemcitabine 10 Bortezomib 10 Lenalidomide 9 Filgrastim 9 Etoposide 8 pembrolizumab 7 Vincristine 7 Paclitaxel 7 Cyclosporine 7 carfilzomib 6 Topotecan 6 Temozolomide 6 Docetaxel 6 Calcium Dobesilate 6 Antilymphocyte Serum 6 pomalidomide 5 fludarabine phosphate 5 Radiotherapy 5 Peripheral Blood Stem Cell Transplantation 5 Pemetrexed 5 Mitoxantrone 5 Granulocyte Colony-Stimulating Factor 5 Doxorubicin 5 Azacitidine 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03683277 2025-02-19

IFM2014-01

Intergroupe Francophone du Myelome

Phase 2 Terminated

Multiple Myeloma, Recurrence, Genetic Diseases, Inborn

Data powered by HemOnc (CC BY 4.0) Colophon ⚡